Irvine-based NeoMend, which is developing wound healing products, disclosed this week via a regulatory filing that it has raised $2.7M out of a $3.5M funding round for the company, consisting of a convertible note along with warrants convertible to preferred stock. According to the filing, the firm's investors continue to include Prospect Venture Partners, Vivo Ventures, Sanderling Ventures, and Novo A/S. More information »